JP4695763B2 - クラミジア抗原および対応するｄｎａ断片ならびにその使用 - Google Patents

クラミジア抗原および対応するｄｎａ断片ならびにその使用 Download PDF

Info

Publication number
JP4695763B2
JP4695763B2 JP2000615762A JP2000615762A JP4695763B2 JP 4695763 B2 JP4695763 B2 JP 4695763B2 JP 2000615762 A JP2000615762 A JP 2000615762A JP 2000615762 A JP2000615762 A JP 2000615762A JP 4695763 B2 JP4695763 B2 JP 4695763B2
Authority
JP
Japan
Prior art keywords
chlamydia
seq
polypeptide
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000615762A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002542827A (ja
JP2002542827A5 (https=
Inventor
アンドリュー、ディー．モーディン
レイモンド、ピー．オーメン
ジョー、ウォン
パメラ、ダン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Original Assignee
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd
Publication of JP2002542827A publication Critical patent/JP2002542827A/ja
Publication of JP2002542827A5 publication Critical patent/JP2002542827A5/ja
Application granted granted Critical
Publication of JP4695763B2 publication Critical patent/JP4695763B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2000615762A 1999-05-03 2000-05-03 クラミジア抗原および対応するｄｎａ断片ならびにその使用 Expired - Fee Related JP4695763B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13227099P 1999-05-03 1999-05-03
US14127699P 1999-06-30 1999-06-30
US60/132,270 1999-06-30
US60/141,276 1999-06-30
PCT/CA2000/000511 WO2000066739A2 (en) 1999-05-03 2000-05-03 Chlamydia antigens and corresponding dna fragments and uses thereof

Publications (3)

Publication Number Publication Date
JP2002542827A JP2002542827A (ja) 2002-12-17
JP2002542827A5 JP2002542827A5 (https=) 2007-03-29
JP4695763B2 true JP4695763B2 (ja) 2011-06-08

Family

ID=26830227

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000615762A Expired - Fee Related JP4695763B2 (ja) 1999-05-03 2000-05-03 クラミジア抗原および対応するｄｎａ断片ならびにその使用

Country Status (8)

Country Link
US (4) US20030095973A1 (https=)
EP (1) EP1177301B1 (https=)
JP (1) JP4695763B2 (https=)
AT (1) ATE375391T1 (https=)
AU (1) AU780444B2 (https=)
CA (1) CA2373021A1 (https=)
DE (1) DE60036698T2 (https=)
WO (1) WO2000066739A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1105489A1 (en) 1998-08-20 2001-06-13 Aventis Pasteur Limited Nucleic acid molecules encoding pomp91a protein of chlamydia
WO2000011181A1 (en) 1998-08-20 2000-03-02 Connaught Laboratories Limited NUCLEIC ACID MOLECULES ENCODING INCLUSION MEMBRANE PROTEIN C OF $i(CHLAMYDIA)
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6649370B1 (en) 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
CA2353107A1 (en) 1998-12-01 2000-06-08 Andrew D. Murdin Chlamydia antigens and corresponding dna fragments and uses thereof
EP1169465B1 (en) * 1998-12-04 2006-03-01 University Of Manitoba Two-step immunization procedure against chlamydia infection
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
JP2002531129A (ja) 1998-12-08 2002-09-24 コリクサ コーポレイション クラミジア感染の処置および診断のための化合物および方法
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
CA2354431A1 (en) * 1998-12-23 2000-07-06 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
JP2002541766A (ja) 1998-12-28 2002-12-10 アベンティス、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
MXPA01009256A (es) 1999-03-12 2003-07-14 Aventis Pasteur Antigenos de chlamydia y fragmentos de acido desoxirribonucleico correspondientes y usos de los mismos.
DE60036698T2 (de) 1999-05-03 2008-07-24 Sanofi Pasteur Ltd., Toronto Chlamydia-antigene und entsprechende dna-fragmente und deren verwendungen
NZ517952A (en) 1999-09-20 2004-01-30 Aventis Pasteur Chlamydia antigens and corresponding DNA fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
AU1375501A (en) * 1999-11-12 2001-05-30 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
EP1240331B1 (en) 1999-12-22 2010-04-07 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US20020082402A1 (en) * 2000-04-04 2002-06-27 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
WO2001081379A2 (en) 2000-04-21 2001-11-01 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
AU2001258105A1 (en) 2000-05-08 2001-11-20 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US20040254130A1 (en) * 2000-05-08 2004-12-16 Murdin Andrew D Chlamydia antigens and corresponding dna fragments and uses thereof
JP2004502415A (ja) 2000-07-03 2004-01-29 カイロン　エセ．ピー．アー． Ｃｈｌａｍｙｄｉａｐｎｅｕｍｏｎｉａｅに対する免疫化
US20080112965A1 (en) * 2001-10-01 2008-05-15 Aventis Pasteur Limited Chlamydia OMP antigen
US8568732B2 (en) 2009-03-06 2013-10-29 Novartis Ag Chlamydia antigens
WO2011063133A1 (en) 2009-11-18 2011-05-26 Auburn University LOW ANTIGEN-DOSE IMMUNIZATION FOR MAXIMIZING T-HELPER CELL 1 (T h1) IMMUNITY AGAINST DISEASE

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1331443C (en) * 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
DE69535914D1 (de) * 1994-09-20 2009-03-26 Hitachi Chemical Co Ltd Polynukleotide die einen antigenes polypeptid aus chlamydia pneumoniae kodieren
FR2726764B1 (fr) * 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale
US5840788A (en) 1997-06-20 1998-11-24 Acushnet Company Ultraviolet light resistant urethane top coat for golf balls
JP4160640B2 (ja) * 1997-06-23 2008-10-01 スヴェンド バークランド クラミジア・ニューモニエ由来の表面露出タンパク質
US7459524B1 (en) * 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
DE69841894D1 (de) 1997-11-21 2010-10-21 Merck Serono Biodevelopment Sa Äusseres Membranpolypeptid von Chlamydia pneumoniae sowie Fragmente davon und deren Verwendung, insbesondere zur Diagnose, Prävention und Behandlung einer Infektion
JP2002536958A (ja) * 1997-11-21 2002-11-05 ジェンセット Ｃｈｌａｍｙｄｉａｐｎｅｕｍｏｎｉａｅゲノム配列およびポリペプチド、それらのフラグメント、ならびに特に感染症の診断、予防および治療のためのそれらの使用
EP2218731A1 (en) 1997-11-28 2010-08-18 Merck Serono Biodevelopment Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
WO2000011181A1 (en) 1998-08-20 2000-03-02 Connaught Laboratories Limited NUCLEIC ACID MOLECULES ENCODING INCLUSION MEMBRANE PROTEIN C OF $i(CHLAMYDIA)
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
MXPA01004291A (es) 1998-10-28 2003-06-09 Aventis Pasteur Antigenos de chlamydia y fragmentos de acido desoxirribonucleico correspondientes y usos de los mismos.
US6822071B1 (en) * 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
CA2350775A1 (en) 1998-11-12 2000-05-18 The Regents Of The University Of California Chlamydia pneumoniae genome sequence
CA2353107A1 (en) 1998-12-01 2000-06-08 Andrew D. Murdin Chlamydia antigens and corresponding dna fragments and uses thereof
JP2002531129A (ja) 1998-12-08 2002-09-24 コリクサ コーポレイション クラミジア感染の処置および診断のための化合物および方法
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
DE60036698T2 (de) 1999-05-03 2008-07-24 Sanofi Pasteur Ltd., Toronto Chlamydia-antigene und entsprechende dna-fragmente und deren verwendungen
NZ517952A (en) 1999-09-20 2004-01-30 Aventis Pasteur Chlamydia antigens and corresponding DNA fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
EP1240331B1 (en) 1999-12-22 2010-04-07 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
AU2138501A (en) 1999-12-22 2001-07-03 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020071831A1 (en) 2000-04-04 2002-06-13 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20030100706A1 (en) 2000-04-04 2003-05-29 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020082402A1 (en) 2000-04-04 2002-06-27 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020132994A1 (en) 2000-04-04 2002-09-19 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020094965A1 (en) 2000-04-04 2002-07-18 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
WO2001081379A2 (en) 2000-04-21 2001-11-01 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20040254130A1 (en) 2000-05-08 2004-12-16 Murdin Andrew D Chlamydia antigens and corresponding dna fragments and uses thereof
AU2001258105A1 (en) 2000-05-08 2001-11-20 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
JP2004502415A (ja) 2000-07-03 2004-01-29 カイロン　エセ．ピー．アー． Ｃｈｌａｍｙｄｉａｐｎｅｕｍｏｎｉａｅに対する免疫化

Also Published As

Publication number Publication date
AU4388500A (en) 2000-11-17
WO2000066739A2 (en) 2000-11-09
EP1177301A2 (en) 2002-02-06
CA2373021A1 (en) 2000-11-09
US7070792B2 (en) 2006-07-04
JP2002542827A (ja) 2002-12-17
US7658934B2 (en) 2010-02-09
EP1177301B1 (en) 2007-10-10
US20040086525A1 (en) 2004-05-06
WO2000066739A3 (en) 2001-01-11
US20090155350A1 (en) 2009-06-18
ATE375391T1 (de) 2007-10-15
US7595058B2 (en) 2009-09-29
AU780444B2 (en) 2005-03-24
US20030095973A1 (en) 2003-05-22
US20050202048A1 (en) 2005-09-15
DE60036698D1 (de) 2007-11-22
DE60036698T2 (de) 2008-07-24

Similar Documents

Publication Publication Date Title
JP4695763B2 (ja) クラミジア抗原および対応するｄｎａ断片ならびにその使用
JP4864264B2 (ja) クラミジア抗原および対応するｄｎａ断片ならびにその使用
JP4667694B2 (ja) クラミジア抗原および対応するｄｎａ断片ならびにその使用
US7629327B2 (en) Chlamydia 60 Kda CRMP antigens and vaccine uses
US20020094340A1 (en) Chlamydia antigens and corresponding dna thereof
US6521745B1 (en) Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US20050002960A1 (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
AU770905B2 (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
JP2002530052A (ja) クラミジア抗原および対応するｄｎａ断片ならびにその使用
JP2003512017A (ja) クラミジア抗原および対応するｄｎａ断片ならびにその使用
AU1053900A (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
JP2002541766A (ja) クラミジア抗原および対応するｄｎａ断片ならびにその使用
JP2002531095A (ja) クラミジア抗原および対応するｄｎａ断片ならびにその使用
WO2001021803A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2001002575A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100519

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100618

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100720

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110128

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110228

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140304

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees